Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA

Table 2 Fixed-effects results of NMA comparing tedizolid with each of the seven comparator drugs (odds ratios [95% credible intervals])

Outcome	Comparator Drug
Outcome	Ceftaroline	Daptomycin	Linezolid	Teicoplanin	Telavancin	Tigecycline	Vancomycin
Clinical response at the end of treatment
All trials	0.7 [0.0, 30.6]	NA	1.0 [0.7, 1.3]	2.2 [0.6, 9.0]	NA	NA	1.7 [1.0, 3.0]
ITT/mITT only	NA	NA	1.0 [0.7, 1.3]	2.2 [0.6, 9.0]	NA	NA	1.5 [0.8, 2.6]
Clinical response at PTE/TOC
All trials	1.0 [0.3, 3.5]	1.4 [0.5, 3.8]	1.0 [0.7, 1.4]	NA	1.4 [0.9, 2.3]	3.2 [0.8, 16.9]	1.6 [1.1, 2.5]
ITT/mITT only	1.0 [0.3, 3.5]	1.4 [0.5, 3.8]	1.0 [0.7, 1.4]	NA	1.4 [0.9, 2.3]	3.2 [0.8, 16.7]	1.6 [1.1, 2.5]
MRSA only	NA	2.1 [0.4, 13.4]	1.0 [0.4, 2.3]	NA	1.1 [0.4, 3.0]	3.2 [0.7, 20.0]	1.6 [0.7, 4.0]
Post hoc sensitivity analysis
MRSA only	1.2 [0.4, 3.6]	2.1 [0.4, 13.5]	1.0 [0.4, 2.3]	NA	1.1 [0.4, 3.0]	3.2 [0.7, 20.0]	1.6 [0.7, 4.0]
Discontinuation due to AE
All trials	0.3 [0.0, 7.1]	0.8 [0.0, 45.8]	0.5 [0.1, 1.9]	NA	0.3 [0.1, 1.3]	NA	0.4 [0.1, 1.8]

Bold text indicates CrI that do not cross 1 and favour tedizolid
AE adverse event, CRI credible intervals, EOT end of treatment, ITT intention to treat, mITT modified intention to treat, MRSA methicillin-resistant Staphylococcus aureus, NA not available, PTE post-treatment evaluation, TOC test of cure

ISSN: 1471-2334